Greenwich LifeSciences’ GLSI-100 Receives FDA Fast Track Designation for Preventing Breast Cancer Recurrence

Greenwich LifeSciences’ GLSI-100 Receives FDA Fast Track Designation for Preventing Breast Cancer Recurrence

Giuseppe Curigliano: The Path to A Successful Career

Giuseppe Curigliano

PRODIGE-13 Trial Results: Do We Really Need 5 Years of CT and CEA Follow-Up in CRC?

PRODIGE-13 Trial Results: Do We Really Need 5 Years of CT and CEA Follow-Up in CRC?

Ophira Ginsburg: Thrilled to join Imperial College London’s School of Public Health

Ophira Ginsburg

Florian Scotté: Fast-Track Safety Evaluation in Anticancer Drug Development

Florian Scotté

Vivek Subbiah: Why Traditional RCT-focused Reviews May Miss the Mark in Precision Medicine Era

Vivek Subbiah, Future of Cancer Treatment

Michelle Mitchell Welcomes Pete Markey as CRUK’s New Executive Director

Michelle Mitchell

Arndt Vogel: Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer

Arndt Vogel

Nagla Karim